Vadim Bichko, Ph.D.
CSO and Scientific Founder
Dr. Bichko is a virologist with over 15 years of antiviral drug discovery and development experience, mainly in the field of viral hepatitis B, C and HIV. Previously, Dr. Bichko was CSO at Viriom, Inc., a late stage HIV therapy development company (San Diego, CA), Director of Research at Idenix (valopicitabine development for HCV), Virology Lead at Scriptgen/Anadys (discovery and development of HBV polymerase and pregenomic RNA encapsidation inhibitors). Prior to that, he held various academic positions at Fox Chase Cancer Center in Philadelphia, Max-Plank Institute for Biochemistry in Munich and University of Hamburg, Germany, conducting HBV and HDV research. He is the author of numerous publications and patents in molecular virology.
VP Translational Research and Clinical Development
Ms. Huyghe has over 20 years of biotech, pharmaceutical, medical device, and diagnostic experience. She has expertise in designing, planning and executing domestic and international Phase I-III clinical trials. Ms. Huyghe's therapeutic areas of expertise include dermatology, hematology/oncology, gastroenterology, hepatology, respiratory, transplantation, and wound healing. Ms. Huyghe has additional experience in research and development, manufacturing, and process development. Most recently, she was Vice President of Clinical Development at Conatus Pharmaceuticals, a company developing treatments for liver diseases. Prior to Conatus, she was Director of Clinical Research at Idun Pharmaceuticals, which was acquired by Pfizer in 2005.
Boris Rogovoy, Ph.D.
Head of Chemistry
Dr. Rogovoy is a medicinal chemist with over 15 years of drug discovery and development experience in the fields of virology, oncology, CNS and metabolic diseases. Prior to joining Chromis, he served as Director of R&D at ChemDiv, Inc. (San Diego, CA), a global pharmaceutical CRO. Under Dr. Rogovoy’s leadership numerous drug discovery programs (HCV, RSV, oncology) were advanced to the clinic. Dr. Rogovoy spent his academic years at the Center for Heterocyclic Compounds, University of Florida and at the Ernst Mario School of Pharmacy, Rutgers University. He received his Ph.D. from University of Tartu, Estonia in 2002. Dr. Rogovoy is an author of over 30 scientific publications and patents.